<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="46851">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01831427</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-326-0101</org_study_id>
    <nct_id>NCT01831427</nct_id>
  </id_info>
  <brief_title>Evaluating the Safety, Pharmacokinetics and Efficacy of GS-5745 in Subjects With Moderate to Severe Ulcerative Colitis</brief_title>
  <official_title>A Phase 1 Double-blind, Randomized, Placebo-Controlled, Staggered, Single and Multiple Ascending Dose, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of GS-5745 in Subjects With Moderate to Severe Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Canada: Health Canada</authority>
    <authority>Canada: Ethics Review Committee</authority>
    <authority>Belgium: Ethics Committee</authority>
    <authority>Belgium: Federal Agency for Medicinal Products and Health Products</authority>
    <authority>Belgium: Institutional Review Board</authority>
    <authority>Belgium: Ministry of Social Affairs, Public Health and the Environment</authority>
    <authority>Hungary: Ministry of Health, Social and Family Affairs</authority>
    <authority>Hungary: Institutional Ethics Committee</authority>
    <authority>Netherlands:  Independent Ethics Committee</authority>
    <authority>Netherlands: Medical Ethics Review Committee (METC)</authority>
    <authority>Netherlands: Ministry of Health, Welfare and Sport</authority>
    <authority>Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)</authority>
    <authority>Moldova: Medicines Agency</authority>
    <authority>Moldova: Ministry of Health</authority>
    <authority>Moldova: National Ethics Committee</authority>
    <authority>Romania: Ethics Committee</authority>
    <authority>Romania: Ministry of Public Health</authority>
    <authority>Romania: National Agency for Medicines and Medical Devices</authority>
    <authority>Romania: National Authority for Scientific Research</authority>
    <authority>Romania: National Medicines Agency</authority>
    <authority>Romania: State Institute for Drug Control</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a staggered, placebo-controlled, single and multiple ascending dose (SAD/MAD) study
      evaluating the safety, tolerability and pharmacokinetics of GS-5745 in patients between ages
      of 18 to 65 years with moderate to severe ulcerative colitis. This study will provide
      valuable data that can help establish the safety, pharmacokinetics and efficacy of GS-5745
      in ulcerative colitis patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will test the safety of the drug and a system has been built into the trial design
      to ensure patient safety.  Patients will be given different concentrations of the drug
      (known as &quot;cohorts&quot;) starting from a lower dose to a higher dose.

      Single-Dose Treatment:

      A thorough assessment of safety and tolerability will be performed before escalating to the
      next higher dose. For example, the first 2 subjects will be dosed in a staggered fashion 24
      hours apart. Provided that there are no significant safety signals up to 24 hours post-dose
      for the first 2 subjects, the remaining 4 subjects will be dosed.  A thorough assessment of
      safety and tolerability (through day 14 post-dose) will be performed by the safety review
      committee before escalating to the next higher dose. Subjects enrolled in a SAD cohort will
      be eligible to participate in a MAD or adaptive MAD cohort if eligibility criteria are met.

      Multiple-Dose Treatment:

      This design follows the same set-up as the Single-Dose Treatment.  Dosing will not commence
      in the first MAD cohort until safety data from the second dose level SAD cohort has been
      reviewed through Day 15. Successive MAD cohorts will only be dosed after safety data from
      the previous, lower dose MAD cohort through Day 43 and the next higher dose SAD cohort
      through Day 15, have been reviewed by the safety review committee. After all participants
      have completed Day 43 in the MAD cohort, and additional adaptive MAD cohort will explore
      once weekly dosing of up to the maximum tolerated MAD dose for 5 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">March 2015</completion_date>
  <primary_completion_date type="Anticipated">February 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Evaluating the safety and tolerability throughout the duration of the study</measure>
    <time_frame>SAD Cohort: through Day 41, MAD/Adaptive MAD Cohort: through Day 71</time_frame>
    <safety_issue>No</safety_issue>
    <description>Safety and tolerability is measured by the incidence of adverse events and graded laboratory abnormalities.
Additional Time Frame Information: From time the Informed Consent Form (ICF) is signed until follow-up visit; expected average of 6 weeks for SAD cohorts and an average of 11 weeks for MAD/Adaptive MAD cohorts.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics (PK) of GS-5745 following SAD and MAD/adaptive MAD doses of GS-5745</measure>
    <time_frame>SAD Cohort: through Day 43; MAD/Adaptive MAD Cohort: through Day 71</time_frame>
    <safety_issue>No</safety_issue>
    <description>GS-5745 PK parameters in plasma will be calculated as applicable:
SAD: AUClast, AUCinf, Cmax
MAD/Adaptive MAD: AUCtau, Cmax, Ctau
PK collection taken at set time points.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of GS-5745 following SAD and MAD/adaptive MAD doses of GS-5745</measure>
    <time_frame>SAD Cohort: through Day 43; MAD/Adpative MAD Cohort: through Day 71</time_frame>
    <safety_issue>No</safety_issue>
    <description>GS-5745 PK parameters will be calculated as applicable: Tmax, Clast, Tlast, CL, V, T1/2, λz
PK collection taken at set time points.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">74</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>GS-5745</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(IV dose at 0.3 mg/kg, 1.0 mg/kg, 2.5 mg/kg, or 5.0 mg/kg)
Subjects:
SAD cohort - single IV dose;
MAD cohort - multiple (three) IV doses every two weeks;
Adaptive MAD cohort - multiple (five) IV doses up to the maximum tolerated MAD dose every week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GS-5745 Placebo (matching IV dose)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects:
SAD cohort - single IV dose;
MAD cohort - multiple (three) IV doses every two weeks;
Adaptive MAD cohort - multiple (five) IV doses every week</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GS-5745</intervention_name>
    <arm_group_label>GS-5745</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GS-5745 Placebo</intervention_name>
    <arm_group_label>GS-5745 Placebo (matching IV dose)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or Female, 18 to 65 years of age

          -  Negative pregnancy test at screening

          -  Documented diagnosis of ulcerative colitis (UC) with a minimum disease extent of 15
             cm from the anal verge

          -  Mayo Score of at least 3 for the SAD cohort and Mayo Score of at least 6 for the MAD
             cohorts

          -  Hepatic panel (aspartate aminotransferase (AST), alanine aminotransferase (ALT),
             total bilirubin, direct bilirubin,

          -  Alkaline phosphatase, lactate dehydrogenase (LDH) ≤ 2 times the ULN)

          -  Serum creatinine ≤ 1.5 times the ULN

          -  Hemoglobin ≥ 10 g/dL (both males and females)

          -  Absolute neutrophil count (ANC) ≥ 1.5 x 109/L (1,500 mm^3)

          -  Platelets ≥ 100 x 109/L

        Exclusion Criteria:

          -  Pregnant or lactating subjects

          -  Exhibit severe UC/ clinically significant active infection

          -  Current use of oral corticosteroids at a dose equivalent to &gt; 20 mg/day of prednisone

          -  Any dose adjustment in oral corticosteroids or oral immunosuppressants (6-MP,
             Azathioprine) , or oral 5-ASA compounds within 30 days of Baseline

          -  Use of rectal formulations of 5-ASA compounds or corticosteroids within 2 weeks prior
             to randomization

          -  Crohn's disease or indeterminate colitis

          -  History of colectomy, partial colectomy, or dysplasia on biopsy

          -  Stool sample positive for Clostridium difficile (C. difficile) toxin, E. coli,
             Salmonella, Shigella, Campylobacter or Yersinia

          -  Treatment with Infliximab, Adalimumab, Natalizumab, Golimumab, Vedolizumab or
             Certolizumab within 8 weeks of randomization

          -  Any chronic medical condition (including, but not limited to, cardiac or pulmonary
             disease) that, in the opinion of the Investigator, would make the subject unsuitable
             for the study or would prevent compliance with the study protocol
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bittoo Kanwar, MD</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yvonne Walker</last_name>
    <email>yvonne.walker@gilead.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Delta Research Partners LLC</name>
      <address>
        <city>Monroe</city>
        <state>Louisiana</state>
        <zip>71201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>318-807-0819</phone>
    </contact>
    <investigator>
      <last_name>Bhandari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Research Institute of Michigan</name>
      <address>
        <city>Chesterfield Township, MI 48047</city>
        <state>Michigan</state>
        <zip>48047</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>586-598-3329</phone>
    </contact>
    <investigator>
      <last_name>Fogel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ehrhardt Clinical Research, LLC</name>
      <address>
        <city>Belton</city>
        <state>Missouri</state>
        <zip>64012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>919-684-1817</phone>
    </contact>
    <investigator>
      <last_name>Onken, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Community Research</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45255</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>513-281-3868</phone>
    </contact>
    <investigator>
      <last_name>Maynard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>615-322-7736</phone>
    </contact>
    <investigator>
      <last_name>Schwartz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCL St. Luc Hospital</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+011-32-27-649-029</phone>
    </contact>
    <investigator>
      <last_name>Olivier Dewit, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+-11 32 16 34 8856</phone>
    </contact>
    <investigator>
      <last_name>Vermeire</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GIRI</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 2K5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>604-688-6332</phone>
    </contact>
    <investigator>
      <last_name>Bressler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LHSC University Campus</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>(519) 663-8500</phone>
    </contact>
    <investigator>
      <last_name>Barnett, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Szegedi Tudomanyegyetem Altalanos Orvostudomanyi Kar</name>
      <address>
        <city>Szeged</city>
        <state>Csongrád</state>
        <zip>6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>. +011-36-20-498-6434</phone>
    </contact>
    <investigator>
      <last_name>Robert Takacs</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Pharma Center of Kenezy Gyula Korhaz Rendelointezet</name>
      <address>
        <city>Debrecen</city>
        <state>Hajdú-Bihar</state>
        <zip>4031</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+011 36 52 51 1857</phone>
    </contact>
    <investigator>
      <last_name>István Varkonyi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Semmelweis Egyetem Altalanos Orvostudomanyi Kar</name>
      <address>
        <city>Budapest</city>
        <state>Pest</state>
        <zip>1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+011 36 20 987 9871</phone>
    </contact>
    <investigator>
      <last_name>Judit Kapocsi, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Drug Research Centre</name>
      <address>
        <city>Balatonfured</city>
        <zip>8230</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+011-36-87-580-116</phone>
    </contact>
    <investigator>
      <last_name>Peterfai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Republican Clinical Hospital</name>
      <address>
        <city>Chisinau</city>
        <zip>2025</zip>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>. +373-79-966-180</phone>
    </contact>
    <investigator>
      <last_name>Sergiu Popa, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+011-31-20-566-3632</phone>
    </contact>
    <investigator>
      <last_name>D'Haens, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Academisch Ziekenhuis Maastricht</name>
      <address>
        <city>Maastricht</city>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+31 43 387 5021</phone>
    </contact>
    <investigator>
      <last_name>Pierik, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute of Pulmonology &quot;Marius Nasta&quot;</name>
      <address>
        <city>Bucharest</city>
        <zip>050159</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+40 21 335 1607</phone>
    </contact>
    <investigator>
      <last_name>Cimpoeru, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Hungary</country>
    <country>Moldova, Republic of</country>
    <country>Netherlands</country>
    <country>Romania</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 9, 2014</lastchanged_date>
  <firstreceived_date>April 8, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ulcerative colitis</keyword>
  <keyword>moderate</keyword>
  <keyword>severe</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
